Skip to content
Clinical Trials – home
Therapeutic area

Skin and subcutaneous tissue disorders – page 67

  • 849 clinical trials
  • 267 recruiting
  • 359 conditions
  • 25 countries

Conditions in this area

359 conditions with trials, the busiest first

Clinical trials in Skin and subcutaneous tissue disorders

849 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

849 clinical trials

Dermatitis atopic+1

Not recruiting

Study on the Effect of a New Moisturiser with Paraffin and Liquid Paraffin on Preventing Eczema Relapse in Children

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Glycerol
  • Sponsor:Aco Hud Nordic AB

Study on the Effectiveness and Safety of MC2-25 Cream for Itching in Chronic Kidney Disease Patients

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Alanyl Glutamine
  • Sponsor:Mc2 Therapeutics Limited

Partial lipodystrophy

Not recruiting

Study on Metreleptin for Patients with Partial Lipodystrophy

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Metreleptin
  • Sponsor:Chiesi Farmaceutici S.p.A.

Dermatitis atopic

Not recruiting

Study on Dupilumab Step-Down Strategy for Maintaining Remission in Adults and Adolescents with Atopic Dermatitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Clobetasol
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of HRO350 for Patients with Mild-to-Moderate Psoriasis

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Pehero
  • Sponsor:Arctic Bioscience AS

Hand dermatitis

Not recruiting

Study on Oral Roflumilast for Treating Chronic Hand Eczema in Adults

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Rigshospitalet

Colitis ulcerative+2

Not recruiting

Study on Long-term Safety of Ustekinumab for Children with Crohn's Disease, Juvenile Psoriatic Arthritis, or Ulcerative Colitis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Ustekinumab
  • Sponsor:Janssen Cilag International

Dermatomyositis+1

Not recruiting

Study on the Effects of Enpatoran for Patients with Dermatomyositis and Polymyositis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Enpatoran
  • Sponsor:Merck Healthcare KGaA

Netherton's syndrome

Not recruiting

Study to Evaluate the Effectiveness of Spesolimab in Treating Patients with Netherton Syndrome

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Psoriasis

Not recruiting

Study on the Effects of Guselkumab on Memory T-Cells in Psoriasis Patients

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Region Midtjylland

Study on Metreleptin for Children Under 6 with Generalized Lipodystrophy and Related Diabetes or High Triglycerides

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Metreleptin
  • Sponsor:Amryt Pharmaceuticals Designated Activity Company

Malignant melanoma

Not recruiting

Study on Nivolumab for Preventing Melanoma Recurrence in Patients with Completely Removed Stage IIB/C Melanoma

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Substances studied in this area

The therapies tested most often in Skin and subcutaneous tissue disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.